LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares in the U.S. District Court for Southern District of California (No: 3:26-cv-04385).
Investors, who purchased a significant amount of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline: September 28, 2026. NASDAQ: CAPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On July 30, 2026, an investor in NASDAQ: CAPR shares filed lawsuit over alleged securities laws violations by Capricor Therapeutics, Inc. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Capricor Therapeutics, Inc. adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, that the FDA had not agreed to those changes before Capricor Therapeutics, Inc. resubmitted the Deramiocel Biologics License Application (“BLA”), that as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel, and that as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
